Table 1.
Baseline demographics and characteristics of the patient population.
| Characteristics | FMT group (n = 34) | Placebo (n = 34) |
|---|---|---|
| Age, years | 67.1 (5.1) | 67.2 (5.1) |
| Male, n (%) | 21 (62%) | 19 (56%) |
| Female, n (%) | 13 (38%) | 15 (44%) |
| Height, cm | 168.0 (7.4) | 168.2 (6.6) |
| Weight, kg | 66.0 (7.3) | 66.6 (7.7) |
| BMI, kg/m2 | 23.4 (2.3) | 23.5 (2.0) |
| Time to onset, years | 2.5 (1.1) | 2.7 (1.1) |
| PSPRS total score | 40.1 (7.6) | 40.1 (6.9) |
| PSPRS-I | 8.9 (2.0) | 8.9 (2.3) |
| PSPRS-II | 5.4 (2.0) | 5.4 (1.8) |
| PSPRS-III | 3.4 (1.1) | 3.4 (1.1) |
| PSPRS-IV | 6.9 (2.3) | 7.0 (2.5) |
| PSPRS-V | 5.9 (1.6) | 5.9 (1.8) |
| PSPRS-VI | 9.6 (3.3) | 9.6 (3.5) |
| PSPRS-V+VI | 15.5 (3.9) | 15.5 (4.0) |
| UPDRS-II | 28.1 (7.5) | 28.0 (7.9) |
| CSS | 14.1 (6.0) | 13.6 (5.7) |
| PAC-QoL | 70.0 (23.2) | 69.4 (21.0) |
| GSRS | 14.2 (6.7) | 14.4 (6.5) |
| SCOPA-AUT | 40.4 (13.0) | 40.2 (12.8) |
| RBDQ-HK | 19.9 (13.3) | 20.2 (13.9) |
| MMSE | 23.8 (2.6) | 23.5 (2.6) |
| MOCA | 18.1 (3.3) | 18.6 (2.7) |
| HAMD | 11.7 (7.3) | 11.4 (5.3) |
| HAMA | 10.7 (6.5) | 11.1 (5.8) |
| NMSS | 53.7 (23.6) | 53.9 (23.2) |
| SEADL | 66.5 (18.9) | 66.5 (16.7) |
| Faecal CALP, ng/mL | 798.1 (181.9) | 806.8 (136.9) |
| Faecal LF, ng/mL | 61.4 (22.0) | 59.4 (23.5) |
| Faecal α1-AT, ng/mL | 489.8 (216.0) | 500.8 (224.4) |
| Faecal zonulin, ng/mL | 2.2 (0.9) | 2.1 (0.6) |
| Serum zonulin, ng/mL | 21.7 (6.6) | 20.6 (5.1) |
| Faecaldopamine, pg/mL | 61.8 (24.0) | 60.8 (24.8) |
Note: Data are mean (SD) or n (%). BMI, Body-mass index; CSS, Constipation Scoring System; FMT, faecal microbiota transplantation; GSRS, Gastrointestinal Symptom Rating Scale; HAMA, Hamilton Anxiety Scale; HAMD, Hamilton Depression Scale; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; PAC-QoL, Patient Assessment of Constipation Quality of Life; PSP-RS, progressive supranuclear palsy–Richardson's syndrome; PSPRS, Progressive Supranuclear Palsy Rating Scale; RBDQ-HK, REM sleep behavior disorder questionnaire-Hong Kong; SCOPA-AUT, Scales for Outcomes in Parkinson's Disease-Autonomic Dysfunction. SEADL, Schwab and England Activities of Daily Living. SD, standard deviation; UPDRS, Unified Parkinson's Disease Rating Scale. Demographic factors and clinical characteristics were compared using chi-square test, Student’s t test, or two-sided Mann–Whitney U-test.